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ABSTRACT
Background: In Japan, the number of asthma deaths has been gradually decreasing. However, in the man-
agement of asthma, there are still some problems originating from patient-related factors and iatrogenic factors,
both of which should be further analyzed.
Methods: We investigated clinical and background characteristics of 164 patients with asthma who were ad-
mitted to our hospital with acute exacerbations, by reviewing their clinical records.
Results: Fifty-two patients had received long-term management (LTM) based on the guidelines (the LTM
group), while 112 had not (the non-LTM group). In patients whose asthma severity had been intermittent (step
1), the proportion of severe and near fatal exacerbations was significantly higher in the non-LTM group than in
the LTM group. However, even in the LTM-group, 23% of mild persistent (step 2) and 38% of moderately and
severely persistent (step 3 & 4) patients had severe or near fatal exacerbations. In these patients, the peak ex-
piratory flow rate significantly improved after discharge, and poor adherence was also significantly higher in the
non-LTM group than in the LTM group. A multivariate analysis revealed that the factors associated with poor
adherence were: 1) no history of previous admission due to asthma exacerbation; 2) the patient was male; and
3) the patient was young (<60 years).
Conclusions: In the LTM group, re-evaluation of the actual severity of asthma and prompt treatment corre-
sponding to the severity of disease should still be encouraged. In the non-LTM group, establishing countermea-
sures against factors causing poor adherence would be the next step in ensuring strong adherence with LTM.
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INTRODUCTION
According to annual reports of the Japan Ministry of
Health, Labour and Welfare, there were 7253 asthma
deaths in 1995. However, this number has been
gradually decreasing, and in 2006, there were a total
of 2770 asthma deaths.1 There is no doubt that distri-
bution of the guidelines for management of asthma
that advocated corticosteroid inhalation therapy has
greatly contributed to the decrease in asthma mortal-
ity. However, some patients with asthma who have lit-
tle understanding of the disease can result in poor ad-
herence with asthma management. It can be consid-
ered iatrogenic if the physician underestimates the
severity of asthma and fails to sufficiently educate the
patient about the importance of long-term manage-
ment. Poor adherence has been considered to be one
reason for poor asthma control, with resultant exacer-
bation possibly leading to death.2 However, asthma
exacerbation may occur even in patients with good
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adherence. Thus in the management of asthma, there
are still problems related to from patients’ factors and
iatrogenic factors, both of which should be further
clarified.
Our hospital is a central regional hospital serving a
community of 50,000. A substantial number of pa-
tients with asthma exacerbation are treated at our
hospital due to the availability of highly advanced
medical services. In the present study, we retrospec-
tively assessed clinical characteristics of the asthma
patients who required hospitalization due to asthma
exacerbation and the state of long-term management
of asthma before the exacerbation. We set out to clar-
ify causative factors of acute exacerbation in patients
with good or poor adherence, respectively. By com-
paring the degree of adherence, the background as-
sociated with poor adherence with asthma manage-
ment is also highlighted, describing the difficulties in
providing long-term management.
METHODS
SUBJECTS
We studied 164 asthma patients admitted to our hos-
pital with acute exacerbation of asthma from January
1, 1998 to December 31, 2004. The indications for ad-
mission are listed in the Appendix. The patients’ clini-
cal records were reviewed to determine the treatment
for the exacerbation, in addition to their outpatient re-
cords. The background characteristics that were as-
sessed included: age, gender, type of asthma, occupa-
tion, long-term management status, asthma control
level before hospitalization (i.e., asthma severity),
cause of the exacerbation, and severity of the exacer-
bation. Furthermore, questionnaires were sent out to
patients who had stopped receiving medical care after
discharge, and their backgrounds and reasons for the
discontinuation of long-term management were ex-
amined.
BACKGROUND FACTOR DEFINITIONS
1) Long-Term Management
Long-term management (LTM) was defined as condi-
tions under which the patients were managed based
on the guidelines of asthma management3; i.e., 1)
regular stepwise management according to asthma
symptoms, regardless of daily monitoring of the peak
expiratory flow (PEF) rate and 2) education about on-
demand inhalation of short acting β2-stimulant for
mild exacerbation. The patients who satisfied the con-
ditions for LTM constituted the LTM group, while pa-
tients who did not satisfy these conditions constituted
the non-LTM group. Patients in whom an asthma at-
tack was the initial presentation of the disease were
assigned to the non-LTM group.
2) Severity of Asthma
For determination of the severity of asthma before
admission, the “Asthma Prevention and Management
Guideline 2003, Japan” (JGL2003) was used.3 In this
study, asthma severity was determined based on the
step corresponding to the worst symptoms andor
lung function, including daily PEF values and daily
variability, during the month before admission. Pa-
tients whose asthma attack was the initial symptom of
the disease were assigned to the unknown severity
group.
3) Severity of Asthma Exacerbation
The severity of asthma exacerbation was also deter-
mined based on the JGL2003 criteria2: mild, moder-
ate, severe, or near fatal asthma, requiring mechani-
cal ventilation or had a PaCO2 of 45 mmHg or more.
STATISTICAL ANALYSIS
The data are expressed as median values (range).
Differences in the parameters were evaluated using
the Mann-Whitney U test or the Wilcoxon signed-
rank test for comparing the 2 groups. Differences in
the proportions between the 2 groups were evaluated
using χ-square analysis. For factor analysis, univari-
ate and multivariate logistic regression analyses were
used. Differences with a p value of less than 0.05
were considered to indicate a statistically significant
difference.
RESULTS
Table 1 shows patient background characteristics.
Before admission, 52 patients had received LTM (the
LTM group) and 112 patients had not (the non-LTM
group). The proportion of males was significantly
higher in the non-LTM group than in the LTM group.
There were significantly more younger patients in the
non-LTM group than in the LTM group. Asthma se-
verity before admission was step 1 (intermittent) in
52 patients (31.7%), ≧step 2 (i.e., mild persistent,
moderate persistent, and severe persistent) in 71 pa-
tients (43.3%), and unknown in the others. The distri-
bution of severity was similar in the non-LTM group
and the LTM group. An asthma attack was the initial
presentation of their asthma in 33 patients (29.5%) in
the non-LTM group. Although there were a greater
number of smokers in the LTM group than in the
non-LTM group; no significant difference could be
found in the incidence of chronic obstructive pulmo-
nary disease (COPD) between the 2 groups. In both
the non-LTM and the LTM groups, this was the first
hospitalization for most patients and there was no sig-
nificant difference between the 2 groups in the fre-
quency of past admissions.
Figure 1 shows the age distribution of the patients
by gender in the non-LTM and the LTM groups, re-
spectively. In the non-LTM group, the patients were
distributed in a wide range, 20―70 age group, how-
ever the number of male patients in the 20―40 age
group was more than any other age groups. In the
LTM group, the 60―70 age group predominated in
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Fig. 1 The age distribution of patients according to gender in the non-LTM group (A) and the LTM group 
(B), respectively.
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Table 1 Characteristics of the patient
TotalStatus of long-term management (LTM) 
LTMNon-LTM
63/101Gender (Male/Female)
＊10/4253/59
52 (16―98) Age (y): Median (Range) 
＊66 (23―98) 45 (16―83) 
111/31/22Type of asthma (Alergic/Non-alergic/Unknown) 
＊25/13/1486/18/8
52/42/27/2/41Severity of asthma before admission (Step1/2/3/4/1st onset/Unknown) 
N.S.22/13/8/1/830/29/19/1/33
74/76/14Smoking habits (Y/N/Unknown) 
＊15/31/659/45/8
25/139COPD (Y/N) 
N.S.5/4720/92
36/37/91Living with pets (Y/N/Unknown) 
N.S.9/9/3427/28/57
122/24/8/3/7Frequency of previous hospitalizations (0/1/2/3/4/＞ 4 times) 
N.S.31/12/4/1/491/12/4/2/3
＊P＜0.05
both genders.
Figure 2A shows the causes of exacerbation by
group. In both groups, airway infection was the most
frequent cause (approximately 60%). Although infec-
tious episodes can usually be observed during the
summer season, they were least common in the sum-
mer in both groups and therefore no seasonal differ-
ence in airway infections between the LTM and the
non-LTM groups (P = 0.329) were found. The num-
ber of admissions was highest in October for the non-
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Fig. 2 A: Causes of exacerbation in the LTM group and the non-LTM group, and seasonal distribution of infec-
tious episodes. Summer: from June to August, Autumn: from September to November, Winter: from December to 
February, Spring: from March to May. B: severity of the exacerbation in the non-LTM group and the LTM group.
LTM group and in January for the LTM group; how-
ever, there was no significant difference in the overall
distribution between the 2 groups (unpublished
data).
Figure 2B shows the distribution of the severity of
asthma exacerbations in the LTM and non-LTM
groups. Moderate exacerbations accounted for 50% of
the attacks in both groups. However, the proportion
of severe plus near fatal exacerbations to that of mild
plus moderate exacerbations tended to be higher in
the non-LTM group than in the LTM group but not
with statistical significance (33% vs. 23%, P < 0.1). The
age distribution did not differ between the 2 severity
groups (median 56.5 years, range, 16―98 years) in the
mild plus moderate exacerbation group versus (me-
dian 45 years) (range, 19―84 years) the severe plus
near fatal group (P = 0.1919).
Figure 3 shows the severity of pre-admission
asthma exacerbation severity in both the non-LTM
group and LTM group. In the non-LTM group, 37%
had severe plus near fatal exacerbations, even in step
1 patients as well as step 3 & 4 patients. In the LTM
group, 38% of step 3 & 4 patients had severe plus near
fatal exacerbations, while only 9% of step 1 patients
had severe plus near fatal exacerbations. Among the
step 1 patients, the proportion of severe plus near fa-
tal exacerbations was significantly lower in the LTM
group than in the non-LTM group (P = 0.0358). Distri-
butions of the severity of asthma exacerbations which
were caused by infection were not significantly differ-
ent between step 1 and≧step 2 patients.
Univariate analysis to determine which factors
were associated with severe plus near fatal exacerba-
tions was performed using the following variables:
smoking habits, type of asthma (allergic or not), age
(over 60 years or not), LTM (yes or no), history of ad-
mission due to asthma exacerbation, cause of the ex-
acerbation (by infection or not), and asthma control
level (severity) based on symptoms or pulmonary
functions. The risk of severe plus near fatal exacerba-
tions tended to decrease with LTM (odds ratio 0.5,
95% CI; 0.225―1.110, P = 0.0885); and other factors did
not indicate a significant relation to the severity of ex-
acerbations.
Figure 4 shows the PEF of 29 patients in the LTM
group at 1 month before admission, at the time of ex-
acerbation, and at discharge (when the PEF values
were probably at their peak). Among the step 1 pa-
tients, the PEF at the time of the exacerbation was
significantly lower than 1 month before admission,
and then improved to a value that was not signifi-
cantly different from that at 1 month before admis-
sion. On the other hand, the PEF of other patients
(i.e. ≧step 2 before admission) was significantly
greater at discharge than at 1 month before admis-
sion. Furthermore, the proportion of≧step 2 patients
treated with leukotriene receptor antagonists (LTRA)
appeared to be greater at the time of discharge (Ta-
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Fig. 3 Relationship between asthma severity, characterized by daily symptoms and/or daily PEF values, and 
severity of the exacerbation on admission in the non-LTM group (upper) and in the LTM group (lower). Severity 
of asthma exacerbation: mild, moderate, severe, and near fatal.
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Fig. 4 Daily best PEF values of 29 LTM group patients monitored during their clinical 
course. Empty squares represent the patient group with asthma severity of step 1 (n＝13), 
and solid square represents the patients group with asthma severity ≧ step 2 (n＝ 16). 
Note that in ≧ step 2 patients, PEF significantly improved after treatment of the 
exacerbation.
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Table 2 Therapy before and after admission in patients who had received LTM
At dischargeBefore admission
≧ Step 2Step 1≧ Step 2Step 1
800
(400―2000)
800
(400―1600)
800
(400―1600)
800
(100―1600)
Dose of ICS (μgBDP/day)
[median (range) ]
400
(200―600) 
400
(200―500) 
400
(100―800) 
300
(150―500) 
Dose of theophyline (mg/day)
[median (range) ]
53.345.543.340.9Percentage of patients given LTRA (%) 
60  36.456.731.8Percentage of patients given long acting β2-stimulant (%) 
ble 2). Regardless of the status of asthma severity,
the dosage of inhaled corticosteroid or theophylline
was not significantly different during the clinical
course.
The adherence rate after discharge is shown in
Figure 5. A marked difference in adherence could be
seen between the non-LTM group and the LTM
group: 48% of the non-LTM patients discontinued
LTM, while only 17% of LTM patients discontinued
LTM (P = 0.0001). The patients’ responses to the
questionnaire indicated that the reason for discon-
tinuing LTM was relief of the symptoms, while some
explained that they had no time or money to spare for
LTM.
A multivariate analysis was used to determine the
factors related to LTM status using the factors identi-
fied as significant in the univariate analysis: age, gen-
der, occupational history, severity of asthma, and his-
tory of admission due to asthma exacerbation. As
shown in Table 3, previous admission and age (over
60 years) were significant factors associated with
good adherence to LTM, while male patients showed
a negative association with LTM adherence (Table
3).
DISCUSSION
The risk for hospitalization due to asthma exacerba-
tion has been reported to be related to psychological
factors4,5 and may be predicted by a past history of
hospitalization due to exacerbation, but not by previ-
ous corticosteroid inhalation therapy.6 Furthermore,
the risk for hospitalization can be decreased by exact
assessment and resolution of poor adherence.7 Since
the subjects studied in the present study involved pa-
tients who required hospitalization due to asthma ex-
acerbation, it could not be concluded that poor adher-
ence was the factor for asthma admission, even
though there were more non-LTM patients than LTM
patients. Therefore, in this study, we targeted our
analyses on clarifying causative factors of acute exac-
erbations in both groups, and clarifying clinical char-
acteristics and background factors relevant to poor
adherence by comparing the characteristics between
the LTM and non-LTM patients.
The most frequent cause of asthma exacerbation in
both the non-LTM and LTM groups was airway infec-
tion, although infection was not a factor associated
with the severe plus near fatal exacerbations. Since
airway infection was a common cause even during
the summer season, measures to prevent infection
due to various organisms, including the influenza vi-
rus, are essential in lowering the risk of asthma exac-
erbation.
It was found in the non-LTM group the proportion
of severe plus near fatal exacerbations to that of mild
plus moderate exacerbations tended to be higher
than in the LTM group, and that 37% of step 1 patents
were hospitalized due to severe and near fatal exacer-
bations. The following situations would be suspected
in the non-LTM group as reasons for this; inappropri-
ate on-demand use of inhaled short acting β2-
agonists, poor control of allergic airway inflamma-
tions and delay in visiting emergency facilities. In the
present study, univariate analysis revealed that adher-
ence with LTM could decrease the risk of severe and
near fatal exacerbations, so that maintaining adher-
ence or improvement of poor adherence with LTM
should be encouraged.
However, even in the LTM group, the rate of se-
vere plus near fatal asthma reached 42.3% in≧step 2
patients, whose PEF values after discharge were sig-
nificantly higher than their PEF values 1 month be-
fore admission. In the present study, the asthma se-
verity was determined based on the symptoms and
or pulmonary functions at 1 month before admission.
Therefore, the findings indicate that asthma manage-
ment had not been appropriate in ≧step 2 patients
even in the LTM group. It has been reported that the
prevalence of asthma symptoms has been substan-
tially underestimated by healthcare professionals.8
Thus, careful evaluation of the actual severity of
asthma and prompt treatment that is appropriate for
the severity of disease should always be encouraged.
In this study, LTRA or inhaled long-acting β2-
stimulants were used for improving asthma manage-
ment in many patients, probably due to the previous
study9-11 reporting that including these therapies to
inhaled corticosteroid (ICS) therapy was more effec-
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Death of the other diseases
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P ＝ 0.0001
Fig. 5 Adherence with asthma management after treatment of the exacerbation in the non-LTM 
group and in the LTM group.
Table 3 Background factors related to adherence (Multivariate analysis)
Odds ratio (95%CI) LevelFactor
P＜0.0033.926 (1.637―9.412) Y/NPrevious admission due to asthma exacerbation
N.S.0.906 (0.358―2.293) Y/NOccupation
P＜0.030.320 (0.127―0.807) M/F Gender
N.S.1.524 (0.661―3.517)Y/NSeverity of asthma (Step 1) 
P＜0.0014.646 (1.959―11.020) Y/NAge (≧60 years) 
tive than doubling the ICS dosage for improving lung
functions.
Turner12 compared the characteristics of patients
who were admitted with near fatal asthma to patients
who were hospitalized due to asthma exacerbations
without respiratory failure and found that there was
no difference between the groups in the degree of air-
way obstruction or bronchial hyperresponsiveness,
and that history of admission to the intensive care
unit, irrespective of the severity of asthma, the failure
to respond to worsening asthma was the risk factor
for near fatal asthma. In the present study, gender,
age, smoking habits, control level in terms of lung
function andor asthma symptoms, and history of ad-
mission due to asthma exacerbation did not appear to
be risk factors for severe plus near fatal exacerba-
tions. This is probably due to complex interactions
among the various factors andor regional differ-
ences, suggesting that epidemiological studies such
as this one might be necessary in each region.
Adherence after discharge declined in the non-
LTM group than in the LTM group, as expected. Rea-
sons for poor adherence with asthma management
have been considered to include: 1) the majority of
patients considering themselves to have controlled
asthma, while actual symptom levels show failure to
reaching the levels expected by management guide-
lines2,13; 2) the patients desire fewer symptoms and
no impact on daily activities but experience difficul-
ties in receiving LTM due to several circumstantial
problems (e.g. problems accessing prescriptions,
cost, competing demands, etc)2; and 3) intentional
poor adherence arises from the patients’ common be-
liefs about illness and treatment or expectations that
influence their motivation to maintain the treatment
regimen.14,15 In the present study, the following items
were identified as possible factors for poor adher-
ence: 1) no history of previous admission due to
asthma exacerbation; 2) the patient is male; and 3)
the patient is young (<60 years). Asthma control lev-
els before admission and occupational history did not
seem to be related to adherence. Thus, the following
Baba K et al.
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countermeasures against poor adherence would be
considered appropriate: 1) helping to make hospital-
ized patients understand that controlling asthma
based on the guidelines will benefit them; 2) thor-
ough and persistent education informing patients that
relief from asthma symptoms does not imply a cure;
3) identifying the reasons for poor control in individ-
ual patients; and 4) paying particular attention to pa-
tients with risk factors that were identified to be sig-
nificant in the present study. Patients may sometimes
feel reluctant to talk to physicians about their eco-
nomic problems or living conditions and therefore
physicians should not hesitate to these issues up with
their patients as the occasion demands. Indeed, iden-
tifying individual patients’ goals has been shown to
encourage patient involvement, which may lead to a
better adherence to therapy.16
On the other hand, three-quarters (74%) of the non-
LTM patients did not respond to the questionnaires.
These non-respondents may represent a group who
have poor psychological adherence or affinity to
medical facilities and may make it very difficult for
medical staff to successfully use the medical ap-
proach in improving such poor adherence.
Successful treatment with inhaled corticosteroids
has been achieved in many patients with asthma,
however it is now time to proceed to the next step in
ensuring a patient’s strong adherence with long-term
management. In order to implement the strategies
identified in this study, family doctors, to whom pa-
tients have easy access, may play an important role.
In addition to a partnership between patients and
healthcare staff, a medical partnership between spe-
cialists and general physicians, for example by shar-
ing the patients’ profiles and performing efficient
medical care, might also be effective for maintaining
strong patient adherence. Furthermore, partnerships
with nursing staff andor pharmacists may also be
important. A prospective study to verify the useful-
ness of such a system would be appropriate.
APPENDIX
In case of the following symptoms and signs of
asthma exacerbation which did not completely re-
spond to inhalation of rapid-acting β2-agonist within
1―2 hours andor systemic administration of corti-
costeroid:
・Symptoms not completely relieved
・PEF <70% personal best or predicted
・Hypoxemia (O2 saturation <93%)
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